Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

NCT02906371 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Lymphoblastic Leukemia, Acute, Childhood

Interventions

DRUG: Tocilizumab
DRUG: Tocilizumab
BIOLOGICAL: CART 19

Sponsor

University of Pennsylvania

Collaborators

[object Object]